BioSpace News Archive

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced that it has granted a stock option to purchase 20,000 shares of common stock to one new employee.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided today details of its plans to report second quarter 2020 financial results on August 3, 2020.

Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that it will host a R&D Webcast for investors and analysts on Monday, July 27 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

Personalis, Inc. announced that, effective on July 15, 2020, the Compensation Committee of its Board of Directors granted non-qualified stock options to purchase an aggregate of 44,600 shares of its common stock and restricted stock units covering an aggregate of 34,800 shares of its common stock to seven new employees under Personalis’ 2020 Inducement Plan.

RB announces the launch of a global initiative to generate high-quality scientific research-based evidence to inform public health recommendations and promote behaviors that improve global hygiene.

Promethera® Biosciences S.A., global innovator in cell-based medicines and liver diseases, and Hao Tian Development Group Limited a diversified investment holding company, through its subsidiary Aceso Life Science Holding Limited, announced that the companies have entered into an agreement to form a joint venture.

Axonics Modulation Technologies, Inc., a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urinary and bowel dysfunction, will report financial results for the second quarter of 2020 after the market closes on Thursday, August 6, 2020.

Emergent BioSolutions Inc. will host a conference call on Thursday, July 30, 2020 at 5:00 pm to discuss the financial results for the second quarter of 2020, recent business developments, revenue guidance for the third quarter of 2020, and financial outlook for full year 2020.

The Clorox Company and Cleveland Clinic announced that they are bringing together their expertise to support public health as society continues to face COVID-19, while helping to instill confidence in the safety of public spaces among caregivers, patients, businesses and communities.

Application Based on First Contemporary Outcomes Study Focused Exclusively on Chronic Heart Failure Patient Population Following a Worsening Event